INOVIO Cash and Short-term Investments Drop to $58.5M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy INO?
Cash, cash equivalents and short-term investments were $58.5M vs. $94.1M as of December 31, 2024. "With our first BLA now under review by the FDA, we are focused on delivering INO-3107 to RRP patients who are desperate for treatment options that reduce reliance on surgery to control this rare and devastating disease," said Dr. Jacqueline Shea, INOVIO's President and Chief Executive Officer. "Our top priority is advancing INO-3107, and to do so, optimizing and extending our financial resources towards our target PDUFA date of October 30, 2026. We are excited about the opportunities ahead as we prepare to become a commercial-stage company and work to leverage the power of partnerships to advance other promising candidates in our pipeline. I look forward to providing more updates on our progress with these efforts in the coming months."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy INO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 1.190
Low
3.00
Averages
7.33
High
13.00
Current: 1.190
Low
3.00
Averages
7.33
High
13.00
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the overstated prospects of the INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, highlighting its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Inovio in the Eastern District of Pennsylvania on behalf of investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, with a deadline of April 7, 2026, for investors to apply as lead plaintiffs, indicating the urgency of legal action.
- Allegations of False Statements: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which could hinder the timely submission of the INO-3107 Biologics License Application (BLA), thereby impacting investor confidence in the company's prospects.
- FDA Review Findings: On December 29, 2025, the FDA accepted Inovio's INO-3107 BLA but noted that the company did not provide adequate information to justify eligibility for accelerated approval, leading to a significant overestimation of the regulatory and commercial prospects by investors.
- Stock Price Plunge Impact: Following the FDA announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share, reflecting a pessimistic market sentiment regarding the company's future, which may further erode investor confidence.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Inovio Pharmaceuticals and certain officers, alleging violations of federal securities laws from October 10, 2023, to December 26, 2025, seeking damages for affected investors.
- False Statements Allegations: The complaint claims that throughout the class period, defendants made materially false and misleading statements regarding the CELLECTRA device's manufacturing deficiencies and the regulatory prospects of INO-3107, leading to investor misjudgment about the company's future.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by April 7, 2026, to participate in potential recovery, with the assurance that they do not need to serve as lead plaintiffs to share in any recovery.
- Law Firm Background: Bronstein, Gewirtz & Grossman LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing its role in restoring market integrity and accountability.
See More
Inovio Pharmaceuticals Investors Class Action Notice
- Class Action Initiated: The Portnoy Law Firm advises Inovio Pharmaceuticals investors of a class action for those who purchased securities between October 10, 2023, and December 26, 2025, with a deadline for lead plaintiff motions set for April 7, 2026, indicating the urgency of legal action.
- False Statement Allegations: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which misled investors regarding the prospects of the INO-3107 Biologics License Application, impacting investor decisions.
- FDA Review Update: On December 29, 2025, the FDA accepted Inovio's INO-3107 Biologics License Application but noted that the company did not provide adequate information to justify eligibility for accelerated approval, highlighting regulatory compliance issues that could affect future market performance.
- Stock Price Volatility: Following the FDA announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share, reflecting a pessimistic market sentiment regarding the company's prospects and significant investor losses.
See More
Class Action Lawsuits Filed for Multiple Companies
- Class Action Notification: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging investors to file lead plaintiff motions by the specified deadlines to protect their legal rights.
- BlackRock TCP Lawsuit Details: The lawsuit alleges that from November 2024 to January 2026, BlackRock failed to timely and appropriately value its investments, resulting in overstated net asset value and investor losses, with a lead plaintiff deadline of April 6, 2026.
- Oracle Lawsuit Issues: In the class action from June to December 2025, Oracle is accused of failing to disclose that its AI infrastructure strategy would lead to significant capital expenditure increases without corresponding revenue growth, with investors suffering losses exceeding $50,000, also with a lead plaintiff deadline of April 6, 2026.
- Paysafe and Inovio Lawsuit Overview: Paysafe's lawsuit highlights significant exposure to high-risk clients potentially impacting revenue growth, while Inovio faces challenges in timely FDA submissions due to manufacturing deficiencies, with lead plaintiff deadlines for both set for April 7, 2026.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026, to participate.
- False Statements Allegations: The complaint alleges that Inovio made false and misleading statements during the class period, indicating manufacturing deficiencies with its CELLECTRA device and suggesting that filing for the INO-3107 BLA by 2H 2024 was unlikely, which led to investor losses.
- FDA Review Issues: Inovio failed to provide sufficient evidence to support a priority review or accelerated approval for its BLA, indicating that its public statements were false and materially misleading throughout the class period, exacerbating investor damages.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to take action before class certification to ensure their rights are protected and avoid being absent class members.
See More
Inovio Pharmaceuticals Securities Class Action Notice
- Class Action Notice: Rosen Law Firm reminds investors who purchased Inovio Pharmaceuticals securities between October 10, 2023, and December 26, 2025, to apply as lead plaintiffs by April 7, 2026, to participate in the class action and potentially receive compensation.
- Lawsuit Background: The lawsuit alleges that Inovio made false and misleading statements during the class period, particularly regarding deficiencies in its CELLECTRA device and the overstated prospects of the INO-3107 Biologics License Application, resulting in investor losses when the truth emerged.
- Law Firm's Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, highlighting its expertise and success in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that merely act as intermediaries, to ensure effective legal representation and support in the class action.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit
- Class Action Initiated: Bragar Eagel & Squire has filed a class action lawsuit against Inovio in the Eastern District of Pennsylvania on behalf of investors who purchased Inovio securities between October 10, 2023, and December 26, 2025, with a deadline of April 7, 2026, for investors to apply as lead plaintiffs, indicating the urgency of legal action.
- Allegations of False Statements: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which could hinder the timely submission of the INO-3107 Biologics License Application (BLA), thereby impacting investor confidence in the company's prospects.
- FDA Review Findings: On December 29, 2025, the FDA accepted Inovio's INO-3107 BLA but noted that the company did not provide adequate information to justify eligibility for accelerated approval, leading to a significant overestimation of the regulatory and commercial prospects by investors.
- Stock Price Plunge Impact: Following the FDA announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share, reflecting a pessimistic market sentiment regarding the company's future, which may further erode investor confidence.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Over Securities Violations
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Inovio Pharmaceuticals and certain officers, alleging violations of federal securities laws from October 10, 2023, to December 26, 2025, seeking damages for affected investors.
- False Statements Allegations: The complaint claims that throughout the class period, defendants made materially false and misleading statements regarding the CELLECTRA device's manufacturing deficiencies and the regulatory prospects of INO-3107, leading to investor misjudgment about the company's future.
- Investor Action: Affected investors are encouraged to apply to be lead plaintiffs by April 7, 2026, to participate in potential recovery, with the assurance that they do not need to serve as lead plaintiffs to share in any recovery.
- Law Firm Background: Bronstein, Gewirtz & Grossman LLC is a nationally recognized firm specializing in securities fraud class actions, having recovered hundreds of millions for investors, emphasizing its role in restoring market integrity and accountability.
See More
Inovio Pharmaceuticals Investors Class Action Notice
- Class Action Initiated: The Portnoy Law Firm advises Inovio Pharmaceuticals investors of a class action for those who purchased securities between October 10, 2023, and December 26, 2025, with a deadline for lead plaintiff motions set for April 7, 2026, indicating the urgency of legal action.
- False Statement Allegations: The lawsuit alleges that Inovio made false and misleading statements during the class period, failing to disclose deficiencies in the manufacturing of its CELLECTRA device, which misled investors regarding the prospects of the INO-3107 Biologics License Application, impacting investor decisions.
- FDA Review Update: On December 29, 2025, the FDA accepted Inovio's INO-3107 Biologics License Application but noted that the company did not provide adequate information to justify eligibility for accelerated approval, highlighting regulatory compliance issues that could affect future market performance.
- Stock Price Volatility: Following the FDA announcement, Inovio's stock price fell by $0.56, or 24.45%, closing at $1.73 per share, reflecting a pessimistic market sentiment regarding the company's prospects and significant investor losses.
See More
Class Action Lawsuits Filed for Multiple Companies
- Class Action Notification: The Law Offices of Frank R. Cruz remind investors of class action lawsuits filed against BlackRock TCP Capital Corp., Oracle Corporation, Paysafe Limited, and Inovio Pharmaceuticals, urging investors to file lead plaintiff motions by the specified deadlines to protect their legal rights.
- BlackRock TCP Lawsuit Details: The lawsuit alleges that from November 2024 to January 2026, BlackRock failed to timely and appropriately value its investments, resulting in overstated net asset value and investor losses, with a lead plaintiff deadline of April 6, 2026.
- Oracle Lawsuit Issues: In the class action from June to December 2025, Oracle is accused of failing to disclose that its AI infrastructure strategy would lead to significant capital expenditure increases without corresponding revenue growth, with investors suffering losses exceeding $50,000, also with a lead plaintiff deadline of April 6, 2026.
- Paysafe and Inovio Lawsuit Overview: Paysafe's lawsuit highlights significant exposure to high-risk clients potentially impacting revenue growth, while Inovio faces challenges in timely FDA submissions due to manufacturing deficiencies, with lead plaintiff deadlines for both set for April 7, 2026.
See More
Inovio Pharmaceuticals Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against Inovio Pharmaceuticals for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between October 10, 2023, and December 26, 2025, with a deadline to contact the firm by April 7, 2026, to participate.
- False Statements Allegations: The complaint alleges that Inovio made false and misleading statements during the class period, indicating manufacturing deficiencies with its CELLECTRA device and suggesting that filing for the INO-3107 BLA by 2H 2024 was unlikely, which led to investor losses.
- FDA Review Issues: Inovio failed to provide sufficient evidence to support a priority review or accelerated approval for its BLA, indicating that its public statements were false and materially misleading throughout the class period, exacerbating investor damages.
- Legal Consultation Opportunity: The Schall Law Firm offers free consultations and encourages affected shareholders to take action before class certification to ensure their rights are protected and avoid being absent class members.
See More
